+48.7%
CI vs MRNA
-11.9%
+60.7%
-32.1%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 5y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -2.0% | -3.9% | +1.9% | -2.0% |
| 7D | -3.0% | -17.6% | +14.6% | -3.0% |
| 30D | -2.7% | -5.1% | +2.4% | -2.7% |
| 3M | +7.4% | +220.8% | -213.4% | +7.3% |
| 6M | +4.3% | +321.7% | -317.4% | +4.0% |
| YTD | +8.7% | +601.3% | -592.6% | +8.2% |
| 1Y | +10.8% | +735.2% | -724.4% | +10.3% |
| 3Y | +10.3% | +170.5% | -160.2% | +11.0% |
| 5Y | +48.7% | -14.6% | +63.4% | +44.1% |
| All | +48.7% | -11.9% | +60.7% | +44.1% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 5y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
5y analysis · Full analysis span regression · 6 months rolling